Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK2248761 WBM · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Periods 1 - 4 | EXPERIMENTAL | Subjects will be randomized in a cross over fashion to receive the GSK2248761 WBM capsule formulation or one of three WBM tablet formulations in one of four sequences. |
| Period 5 | EXPERIMENTAL | Subjects in Part B will receive a formulation of GSK2248761 200mg WBM Tablet chosen from Periods 1 - 4 in part A in the fed state (moderate fat meal). |
| Name | Type | Description |
|---|---|---|
| GSK2248761 WBM Capsule | DRUG | 200 mg GSK2248761 WBM capsule (reference) 2 X100mg |
| GSK2248761 WBM Tablet Formulation 1 | DRUG | GSK2248761 WBM Tablet 200mg manufacturing process 1 |
| GSK2248761 WBM Tablet Formulation 2 | DRUG | GSK2248761 WBM Tablet 200mg manufacturing process 2 |
| GSK2248761 WBM Tablet Formulation 3 | DRUG | GSK2248761 WBM Tablet 200mg manufacturing process 3 |
| GSK2248761 WBM Tablet | DRUG | GSK2248761 WBM tablet 200mg manufacturing process 1, 2, or 3 chosen from Period 1 - 4 |
Inclusion Criteria: * Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, vital signs, laboratory tests, and ECGs. A subject with a clinical abnormality or laboratory parameters outside the reference range ...
GSK2248761 WBM is an investigational small molecule being developed for infections, including Human Immunodeficiency Virus (HIV) and Herpesviridae infections. It is in Phase 1 clinical development and has not been approved by regulatory authorities.
GSK2248761 WBM is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker GSK. The drug is currently in Phase 1 clinical development for infectious disease indications.
GSK2248761 WBM is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. One Phase 1 trial has been completed, and no active trials are currently listed.
GSK2248761 WBM has one completed clinical trial, NCT01209117, titled "A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435." This Phase 1 study enrolled 24 healthy adult subjects in the United States.
GSK2248761 WBM is a formulation of the drug GSK2248761. The trial NCT01209117 specifically assessed the relative bioavailability of tablet formulations of GSK2248761, indicating that WBM refers to a particular tablet formulation of the same active compound.